Manufacturing

Articles

The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.

Update on Storm Damage to Pfizer Facility in North Carolina

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Problems continue despite actions by regulators to better prevent and address drug shortages.

Drug Shortages Continue to Plague FDA and Manufacturers

Suzanne Shelley is contibuting editor to 

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

Reducing Vulnerabilities in Upstream and Downstream Supply Chains

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Vaccine Nationalism Escalating Risk

Myrna Wilson, director, Global Marketing, Strategic Growth and Technical Sales, Pharmaceutical Ingredients, Univar Solutions, discusses the state of the biopharma supply chain, movements in the patent industry, and more.

Investigating the Pharmaceutical Ingredients Industry with Myrna Wilson (DCAT Week 2023)

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

Exploring Drug Storage, Drug Dosage, and the Supply Chain with Ulrike Lemke (DCAT Week)

The event, cosponsored by FDA and USP, hosted regulators and industry leaders to discuss the challenges in strengthening the medical product supply chain.

Collaboration Key at the APEC Medical Product Supply Chain Dialogue Event 

A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience. 

Suppliers’ Supply Chains and Continuous Manufacturing Pose Big Risks for US CDMOs

Stockpiling excess inventory is no longer enough to respond to supply chain volatility. 